Asthma drug by GSK given green light for use in China
Pharmaceutical company GSK announced on Wednesday that its novel targeted biological agent Nucala has been approved in China to treat a type of severe asthma.
Nucala will be used for maintenance treatment of severe eosinophilic asthma (SEA) in adults and adolescents aged 12 and above.
SEA accounts for the largest number of severe asthma cases.
The drug is expected to provide an advanced disease management approach for millions of Chinese patients suffering from this respiratory disease, said the company.
GSK said the approval was given following an independent, Phase III clinical trial involving Chinese patients that yielded positive results.
There are roughly 46 million adults in China who suffer from asthma, with about 6 percent suffering from severe asthma.
- China urges sound epidemic control work ahead of May Day holiday
- Hanjiang River in South China sees 3rd flood of 2024
- China's Shenzhou XVII astronauts complete handover, returning to Earth soon
- China works to reduce compulsory education dropout rates
- China to launch anti-bullying campaign in schools
- Shanghai escalator accident: Woman out of ICU